ORIGINAL RESEARCH
Accepted on 27 May 2025
The TNFa-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in Rheumatoid Arthritis patients
doi 10.3389/fimmu.2025.1549781
- 348 views
- Frontiers in Immunology
- Vaccines and Molecular Therapeutics
- Research Topics
- Advances in Immunogenicity Risk Assessment, Monitoring and Mitigation of Biologics
Advances in Immunogenicity Risk Assessment, Monitoring and Mitigation of Biologics
2,235
Total downloads
12k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
PERSPECTIVE
Accepted on 23 May 2025
Immunogenicity of Therapeutic Peptide Products: Bridging the Gaps Regarding the Role of Product-Related Risk Factors
doi 10.3389/fimmu.2025.1608401
- 289 views
SYSTEMATIC REVIEW
Published on 22 May 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
doi 10.3389/fimmu.2025.1581153
- 3,150 views
ORIGINAL RESEARCH
Published on 20 Mar 2025
The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring
doi 10.3389/fimmu.2025.1550655
- 813 views
ORIGINAL RESEARCH
Published on 27 Feb 2025
Antidrug antibodies to adalimumab do not associate with immunologically related adverse events
doi 10.3389/fimmu.2024.1457993
- 1,453 views
ORIGINAL RESEARCH
Published on 13 Feb 2025
A single point mutation on FLT3L-Fc protein increases the risk of immunogenicity
doi 10.3389/fimmu.2025.1519452
- 1,423 views
ORIGINAL RESEARCH
Published on 10 Dec 2024
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
doi 10.3389/fimmu.2024.1496169
- 1,450 views
- 1 citation
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
You will be redirected to our submission process.